Clinical trials: Tolerability
Glaucoma, Ocular Hypertension
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
This purpose of this study is to access the efficacy, tolerability and safety of RKI983 (0.05% and 0.10%) ophthalmic solution bid versus once daily latanoprost 0.005%, in patients with POAG or ocular hypertension.
- Trial name
- NCT00846989
- Testing
- RKI983A, Latanoprost
- Where
- 29 sites in United States
- Volunteers
- 276 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia, Autism-Related Irritability
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
The purpose of this study is to evaluate the long-term safety and tolerability of Xanomeline and Trospium Chloride for the treatment of psychiatric disorders in children and adolescents
- Trial name
- NCT07424404
- Testing
- KarXT, KarX-EC
- Where
- 104 sites in United States, Australia and 9 more
- Volunteers
- 400 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Peanut Allergies
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
The goal of this clinical trial is to evaluate the safety, pharmacokinetics, and effectiveness of MY006, a therapy designed to prevent severe or potentially life-threatening allergic reactions caused by accidental peanut intake.
- Trial name
- NCT07287033
- Testing
- MY006 Low Dose, MY006 Mid Dose, MY006 High Dose
- Where
- 9 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mabylon AG
Respiratory Syncytial Virus Infections
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ALS-008176 following oral administration of single ascending dose of ALS-008176 in healthy Japanese adult participants.
- Trial name
- NCT02478333
- Testing
- ALS-008176 (250 mg), ALS-008176 (500 mg), ALS-008176 (750 mg)
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutical K.K.
Hypertension
Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension
The purpose of this study is to evaluate the safety, efficacy, and tolerability of azilsartan medoxomil, once daily (QD), in individuals with hypertension.
- Trial name
- NCT00362115
- Testing
- Azilsartan Medoxomil, Olmesartan
- Where
- 54 sites in United States, Argentina and 2 more
- Volunteers
- 449 people
- Sponsor
- Takeda
Cystic Fibrosis
Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients
Assessment of the safety, tolerability and early signs of efficacy of three times a day orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients not on treatment with Orkambi
- Trial name
- NCT02170025
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 10 sites in United States, Belgium and 5 more
- Volunteers
- 21 people
- Sponsor
- Bayer
Agitation Associated With, Alzheimer's Disease
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
To compare the efficacy of 2 fixed doses of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type.
- Conditions
- Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder
- Trial name
- NCT01862640
- Testing
- Brexpiprazole, OPC-34712
- Where
- 85 sites in United States, Croatia and 5 more
- Volunteers
- 433 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy
A Study to Evaluate Safety, Tolerability and Pharmacokinetic of ND-003 Tablets in Healthy Adults
The purpose of this study is to evaluate Safety, Tolerability and Pharmacokinetic of ND-003 tablets in Healthy Adults
- Trial name
- NCT06360874
- Testing
- ND-003 40mg, ND-003 80mg, ND-003 160mg
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Shenzhen NewDEL Biotech, Co., Ltd
Crohn's Disease
Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease
The study will examine the safety and effectiveness of brodalumab for the treatment of moderate to severe Crohn's disease. Participants will randomly assigned to receive either brodalumab or placebo (a lookalike liquid that…
- Trial name
- NCT01150890
- Testing
- Brodalumab
- Where
- 50 sites in United States, Australia and 6 more
- Volunteers
- 130 people
- Sponsor
- Amgen
HIV Pre-exposure Prophylaxis
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)
The goal of this clinical study is to learn more about the study drug lenacapavir (LEN), safety, tolerability, and pharmacokinetics (how LEN is absorbed, modified, distributed, and removed from the body of the participants) of…
- Trial name
- PURPOSE 365 (NCT07047716)
- Testing
- Lenacapavir Injection, Lenacapavir Tablet
- Where
- 31 sites in United States
- Volunteers
- 339 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Healthy Subjects
A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults
This study is to evaluate safety, tolerability, pharmacokinetics and effect of food on ABBV-7828 compared to placebo in healthy adult participants.
- Trial name
- NCT07856706
- Testing
- ABBV-7828
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AbbVie
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL
This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/ pharmacodynamics (PK/ PD) of KT-413 in patients with R/R NHL.
- Conditions
- Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, DLBCL, MYD88 Gene Mutation
- Trial name
- NCT05233033
- Testing
- KT-413
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 7 people
- Sponsor
- Kymera Therapeutics, Inc.
Kidney Transplantation
A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation
The purpose of the study is to assess the Pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of ASKP1240 when administered to subjects who received a de novo kidney transplant.
- Trial name
- NCT01279538
- Testing
- bleselumab
- Where
- 21 sites in United States
- Volunteers
- 50 people
- Sponsor
- Astellas Pharma Inc
Hypertension, Dyslipidemia
A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers
A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers
- Trial name
- NCT07682948
- Testing
- Investigational Product 1, Investigational Product 2, Investigational Product 1 + Investigational Product 2
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Korea United Pharm. Inc.
Melanoma, Cutaneous Malignant
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the…
- Trial name
- SUPRAME (NCT06743126)
- Testing
- IMA203, nivolumab plus relatlimab, lifileucel
- Where
- 71 sites in United States, Canada and 4 more
- Volunteers
- 360 people
- Sponsor
- Immatics US, Inc.
Healthy, Chronic Stable Illness
COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers
The primary objectives of the study are: To evaluate the extent of effect, if any, of REGN10933+REGN10987 administration on vaccine-induced neutralizing antibody responses to SARS-CoV-2 by Moderna mRNA-1273 To evaluate the time…
- Trial name
- NCT04852978
- Testing
- casirivimab+imdevimab, Moderna mRNA-1273 vaccine
- Where
- 6 sites in United States
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Cocaine Use Disorder
Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056
This is a study to assess safety, tolerability and interactions of AFQ056 and cocaine in patients with cocaine use disorder.
- Trial name
- NCT04771143
- Testing
- AFQ056
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis
Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)
This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with ALS.
- Trial name
- NCT04569435
- Testing
- ANX005
- Where
- 8 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- Annexon, Inc.
Post-Operative Nausea and Vomiting (PONV)
Single Dose Safety Study for Compound to Treat Post-Operative Nausea and Vomiting (PONV)
The purpose of this study is to describe the safety and tolerability and pharmacokinetics of a single intravenous administration of the new, Sulfobutyl Ether-7-Beta-Cyclodextrin (Captisol™) based, formulation in Healthy Adult…
- Trial name
- NCT01290133
- Testing
- GW597599
- Where
- Australia
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Accenture
Uncomplicated Plasmodium Falciparum Malaria
Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria
This study aimed to determine the efficacy, safety and tolerability of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in pediatric patients (6 months to < 18 years of…
- Trial name
- KALUMI (NCT04546633)
- Testing
- KAF156, LUM-SDF, Coartem
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 3 more
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals